Tavistock Appeal: Decision on Puberty Blockers Will Take Time 

Jess Glass

June 25, 2021

An NHS trust challenging a landmark ruling over the use of puberty-blocking drugs for children faces a wait to find out if the bid was successful after the Court of Appeal retired to consider its decision.

The High Court previously ruled that children under 16 with gender dysphoria can only consent to the use of hormone-blocking treatments if they can understand the “immediate and long-term consequences”.

However, the judges said it was “highly unlikely” that a child aged 13 or under would be able to consent to the treatment, and that it was “doubtful” that a child of 14 or 15 would understand the consequences.

The original case was brought by Keira Bell – a 24-year-old woman who began taking puberty blockers when she was 16 before later “detransitioning” – against the Tavistock and Portman NHS Foundation Trust, which runs the UK’s only gender identity development service for children.

A mother of an autistic teenager who is on the waiting list for treatment, only known as Mrs A, supported Ms Bell in their successful legal challenge.

The Tavistock and Portman NHS Foundation Trust challenged the ruling, which was heard over two days at the Court of Appeal.

Fenella Morris QC, for the trust, outlined the reasons for the appeal in written arguments, noting that puberty blockers are used “to reduce distress” for children with gender dysphoria, allowing them to make decisions about their bodies in the future.

Kids Should Understand Cross-Sex Hormones Before Taking Puberty Blockers 

Jeremy Hyam QC, representing Ms Bell and Mrs A, said that policies and procedures at the Tavistock “as a whole failed to ensure, or were insufficient to ensure, proper consent was being given by children who commenced on puberty blockers”.

The barrister also told the court there was an “inevitable or inextricable progression” from puberty blockers onto cross-sex hormones and that the judges were right to say a child would need to understand the impact of cross-sex hormones before being allowed the puberty-blocking treatment.

Ms Morris had previously told the court it was not inevitable for a young person to move onto cross-sex hormones after 16 though a majority did do so.

The Court of Appeal heard the Tavistock does not provide puberty blockers itself but instead makes referrals to two other NHS trusts – University College London Hospitals and Leeds Teaching Hospitals – who then prescribe the treatments.

John McKendrick QC, for the other trusts, told the court the median age for consenting to puberty blockers is 14.6 for UCL and 15.9 for Leeds.

Ruling Will 'Take a Little While'

At the end of the hearing on Thursday, the Lord Chief Justice Lord Burnett said the court’s ruling will take “a little while”.

Lord Burnett, sitting with Sir Geoffrey Vos and Lady Justice King, said: “We will of course take time to consider our decision.

“We are not in a position to say how long it will take us to produce our judgments, you have given us a lot to think about.”

This article contains information from PA Media.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: